Zutectra

Zutectra is a human hepatitis B immunoglobulin used to prevent hepatitis B virus reinfection in liver transplant patients. This passive immunization provides rapid antibodies against HBV. Suitable for post-transplant prophylaxis.

Zutectra is used to prevent hepatitis B virus (HBV) reinfection in patients who have undergone liver transplantation due to HBV-related liver disease. It provides passive immunization by supplying antibodies against HBV, helping to maintain viral suppression during the critical post-transplant period. This medication is specifically indicated for individuals at high risk of HBV recurrence following liver transplant surgery.

Zutectra works by delivering pre-formed antibodies that bind to hepatitis B virus particles in the bloodstream. This action helps neutralize the virus and may reduce the likelihood of reinfection in transplant patients. The effects are temporary, as the body does not produce these antibodies itself, requiring regular administration to maintain protection.

Zutectra should be handled with care to avoid contamination or infection. It is administered via subcutaneous injection, typically under medical supervision. Patients should be monitored for signs of allergic reactions or infusion-related issues. Always inform healthcare providers about any known allergies or medical conditions before use.

No specific drug interactions have been established for Zutectra. However, as with any immunoglobulin, caution is advised when administering live vaccines, as the antibodies may interfere with vaccine effectiveness. Consult a healthcare provider before combining with other medications or treatments.